FluMist Storage Concerns Discourage Coverage Recommendation From ACIP
Executive Summary
The American Academy of Pediatrics plans not to recommend use of MedImmune/Wyeth's FluMist intranasal flu vaccine over injectable vaccine due to storage concerns, AAP Committee of Infectious Diseases Chair Jon Abramson, MD, Wake Forest University, said
You may also be interested in...
Aventis Pegs Injectable Flu Vaccine As Key Sales Growth Driver
Aventis Pasteur sees increased utilization of its injectable influenza vaccine as a key sales driver for the company going forward
Aventis Pegs Injectable Flu Vaccine As Key Sales Growth Driver
Aventis Pasteur sees increased utilization of its injectable influenza vaccine as a key sales driver for the company going forward
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
MedImmune will initiate a 60,000-patient, open-label safety study for FluMist by Sept. 30 as a Phase IV commitment following the June 17 approval of the intranasal flu vaccine